News Channels

11 Jun 2022 GSK announces positive pivotal phase III data for its respiratory syncytial virus (RSV) vaccine candidate for older adults
10 Jun 2022 Keymed Biosciences Announces Dosing of First Patient in Phase I Trial of Bispecific Antibody CM350
10 Jun 2022 Positive clinical results of ACP-001 presented at EHA2022
10 Jun 2022 Data supports further development of CYT-338 in relapsed/refractory multiple myeloma
10 Jun 2022 Janssen Presents Updated Results Evaluating First-in-Class GPRC5D Bispecific Antibody Talquetamab in Heavily Pretreated Patients with Multiple Myeloma
10 Jun 2022 Wugen Presents New Preclinical Data Demonstrating Enhanced Anti-Tumor Activity of WU-NK-101 at the European Hematology Association (EHA) 2022 Hybrid Congress
10 Jun 2022 Janssen Presents Updated Data at EHA for Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma
10 Jun 2022 Affimed Presents Preclinical Data of Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)
10 Jun 2022 European Commission approves Roche’s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer
10 Jun 2022 Tonix Pharmaceuticals Announces Data Presentations Involving TNX-1500 (Fc-modified anti-CD40L mAb) for the Prevention of Rejection in Kidney and Heart Allograft Transplantation in Animal Models at the 2022 American Transplant Congress
10 Jun 2022 Samsung Bioepis Presents New Phase 3 Study of SB12 (Eculizumab), A Proposed Biosimilar to Soliris, at the European Hematology Association (EHA) Congress 2022
10 Jun 2022 Degron Therapeutics Raises $22M Series A Financing to Accelerate Growth and Expand Molecular-Glue-Based Targeted Protein Degradation Drug Discovery Platform
10 Jun 2022 Seelos Therapeutics Announces Data Demonstrating Statistically Significant Downregulation of mRNA and Reduction of Alpha Synuclein in an In Vitro Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 in Dementia with Lewy Bodies
10 Jun 2022 Amytrx Therapeutic's AMTX-100 CF3 Moves to Phase II Clinical Trial for Atopic Dermatitis
10 Jun 2022 Alnylam Reports Positive Topline Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
10 Jun 2022 ADC Therapeutics Announces Results from Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) in Relapsed or Refractory Hodgkin Lymphoma
08 Jun 2022 Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and Gene Editing for the Treatment of Cancer
08 Jun 2022 Harbour BioMed Announces IND Approval for B7H4x4-1BB Bispecific Antibody
08 Jun 2022 Innovent Announces Phase 2 study of Mazdutide(IBI362) in Chinese Participants with Overweight or Obesity Met Primary and All Key Secondary Endpoints
08 Jun 2022 OnCusp Therapeutics and Multitude Therapeutics Enter into an Ex-China Licensing Agreement for a Potentially Highly Differentiated CDH6-Targeting Antibody Drug Conjugate

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up